SOU 001

Drug Profile

SOU 001

Alternative Names: AA 10020; DRP 001; Stress incontinence therapy - Arachnova/Sosei

Latest Information Update: 17 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Arachnova
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stress incontinence

Most Recent Events

  • 15 May 2006 Discontinued - Phase-I for Stress incontinence in USA (PO)
  • 15 May 2006 Discontinued - Phase-II for Stress incontinence in United Kingdom (PO)
  • 17 May 2005 Sosei has completed phase I clinical trials in stress urinary incontinence in the United Kingdom and the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top